1987 …2020

Research output per year

If you made any changes in Pure these will be visible here soon.

Research Output

Filter
Article
2020

Cardiac Safety of the Trastuzumab Biosimilar ABP 980 in Women with HER2-Positive Early Breast Cancer in the Randomized, Double-Blind, Active-Controlled LILAC Study

Kolberg, H. C., Colleoni, M., Demetriou, G. S., Santi, P., Tesch, H., Fujiwara, Y., Tomasevic, Z. & Hanes, V., Jan 1 2020, (Accepted/In press) In : Drug Safety.

Research output: Contribution to journalArticle

Open Access
2019

Adjuvant letrozole and tamoxifen alone or sequentially for postmenopausal women with hormone receptor-positive breast cancer: Long-term follow-up of the BiG 1-98 trial

BIG 1-98 Collaborative Group and the International Breast Cancer Study Group, Jan 10 2019, In : Journal of Clinical Oncology. 37, 2, p. 105-114 10 p.

Research output: Contribution to journalArticle

Adjuvant Letrozole and Tamoxifen Alone or Sequentially for Postmenopausal Women With Hormone Receptor-Positive Breast Cancer: Long-Term Follow-Up of the BIG 1-98 Trial

members of the BIG 1-98 Collaborative Group and the International Breast Cancer Study Group, Jan 10 2019, In : Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 37, 2, p. 105-114 10 p.

Research output: Contribution to journalArticle

Adjuvant Letrozole and Tamoxifen Alone or Sequentially for Postmenopausal Women With Hormone Receptor-Positive Breast Cancer: Long-Term Follow-Up of the BIG 1-98 Trial

Ruhstaller, T., Giobbie-Hurder, A., Colleoni, M., Jensen, M-B., Ejlertsen, B., de Azambuja, E., Neven, P., Láng, I., Jakobsen, E. H., Gladieff, L., Bonnefoi, H., Harvey, V. J., Spazzapan, S., Tondini, C., Del Mastro, L., Veyret, C., Simoncini, E., Gianni, L., Rochlitz, C., Kralidis, E. & 10 others, Zaman, K., Jassem, J., Piccart-Gebhart, M., Di Leo, A., Gelber, R. D., Coates, A. S., Goldhirsch, A., Thürlimann, B., Regan, M. M. & Group, M. O. T. BIG. . C. G. A. T. I. B. C. S., Jan 10 2019, In : Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 37, 2, p. 105-114 10 p.

Research output: Contribution to journalArticle

A phase II randomized study of neoadjuvant letrozole plus alpelisib for hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer (NeO-ORB)

Mayer, I. A., Prat, A., Egle, D., Blau, S., Alejandro Perez Fidalgo, J., Gnant, M., Fasching, P. A., Colleoni, M., Wolff, A. C., Winer, E. P., Singer, C. F., Hurvitz, S., Estevez, L. G., Van Dam, P. A., Kummel, S., Mundhenke, C., Holmes, F., Babbar, N., Charbonnier, L., Diaz-Padilla, I. & 3 others, Vogl, F. D., Sellami, D. & Arteaga, C. L., Jan 1 2019, In : Clinical Cancer Research. 25, 10, p. 2975-2987 13 p.

Research output: Contribution to journalArticle

Open Access

Clinical and analytical validation of Ki-67 in 9069 patients from IBCSG VIII + IX, BIG1-98 and GeparTrio trial: systematic modulation of interobserver variance in a comprehensive in silico ring trial

Denkert, C., Budczies, J., Regan, M. M., Loibl, S., Dell’Orto, P., von Minckwitz, G., Mastropasqua, M. G., Solbach, C., Thürlimann, B., Mehta, K., Blohmer, J. U., Colleoni, M., Müller, V., Klauschen, F., Ataseven, B., Engels, K., Kammler, R., Pfitzner, B. M., Dietel, M., Fasching, P. A. & 1 others, Viale, G., Aug 15 2019, In : Breast Cancer Research and Treatment. 176, 3, p. 557-568 12 p.

Research output: Contribution to journalArticle

Cyclin E1 expression and palbociclib efficacy in previously treated hormone receptor-positive metastatic breast cancer

Turner, N. C., Liu, Y., Zhu, Z., Loi, S., Colleoni, M., Loibl, S., DeMichele, A., Harbeck, N., André, F., Bayar, M. A. M., Michiels, S. P., Zhang, Z., Giorgetti, C., Arnedos, M., Bartlett, C. H. & Cristofanilli, M., Jan 1 2019, In : Journal of Clinical Oncology. 37, 14, p. 1169-1178 10 p.

Research output: Contribution to journalArticle

Open Access

Endocrine-responsive lobular carcinoma of the breast: Features associated with risk of late distant recurrence

Conforti, F., Pala, L., Pagan, E., Viale, G., Bagnardi, V., Peruzzotti, G., De Pas, T., Bianco, N., Graffeo, R., Rocco, E. G., Vingiani, A., Gelber, R. D., Coates, A. S., Colleoni, M. & Goldhirsch, A., Dec 30 2019, In : Breast Cancer Research. 21, 1, 153.

Research output: Contribution to journalArticle

Open Access

Long-term pooled safety analysis of palbociclib in combination with endocrine therapy for HR1/HER2- Advanced breast cancer

Diéras, V., Rugo, H. S., Schnell, P., Gelmon, K., Cristofanilli, M., Loi, S., Colleoni, M., Lu, D. R., Mori, A., Gauthier, E., Bartlett, C. H., Slamon, D. J., Turner, N. C. & Finn, R. S., Jan 1 2019, In : Journal of the National Cancer Institute. 111, 4, djy109.

Research output: Contribution to journalArticle

Open Access

Neoadjuvant degarelix versus triptorelin in premenopausal patients who receive letrozole for locally advanced endocrine-responsive breast cancer: A randomized phase II trial

International Breast Cancer Study Group, Feb 10 2019, In : Journal of Clinical Oncology. 37, 5, p. 386-395 10 p.

Research output: Contribution to journalArticle

Neoadjuvant letrozole plus taselisib versus letrozole plus placebo in postmenopausal women with oestrogen receptor-positive, HER2-negative, early-stage breast cancer (LORELEI): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial

Saura, C., Hlauschek, D., Oliveira, M., Zardavas, D., Jallitsch-Halper, A., de la Peña, L., Nuciforo, P., Ballestrero, A., Dubsky, P., Lombard, J. M., Vuylsteke, P., Castaneda, C. A., Colleoni, M., Santos Borges, G., Ciruelos, E., Fornier, M., Boer, K., Bardia, A., Wilson, T. R., Stout, T. J. & 6 others, Hsu, J. Y., Shi, Y., Piccart, M., Gnant, M., Baselga, J. & de Azambuja, E., Sep 1 2019, In : The Lancet Oncology. 20, 9, p. 1226-1238 13 p.

Research output: Contribution to journalArticle

Neoadjuvant letrozole plus taselisib versus letrozole plus placebo in postmenopausal women with oestrogen receptor-positive, HER2-negative, early-stage breast cancer (LORELEI): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial: The Lancet Oncology

Saura, C., Hlauschek, D., Oliveira, M., Zardavas, D., Jallitsch-Halper, A., de la Peña, L., Nuciforo, P., Ballestrero, A., Dubsky, P., Lombard, J. M., Vuylsteke, P., Castaneda, C. A., Colleoni, M., Santos Borges, G., Ciruelos, E., Fornier, M., Boer, K., Bardia, A., Wilson, T. R., Stout, T. J. & 6 others, Hsu, J. Y., Shi, Y., Piccart, M., Gnant, M., Baselga, J. & de Azambuja, E., 2019, In : Lancet Oncol.. 20, 9, p. 1226-1238 13 p.

Research output: Contribution to journalArticle

Overall survival with ribociclib plus endocrine therapy in breast cancer

Im, S. A., Lu, Y. S., Bardia, A., Harbeck, N., Colleoni, M., Franke, F., Chow, L., Sohn, J., Lee, K. S., Campos-Gomez, S., Villanueva-Vazquez, R., Jung, K. H., Chakravartty, A., Hughes, G., Gounaris, I., Rodriguez-Lorenc, K., Taran, T., Hurvitz, S. & Tripathy, D., Jul 25 2019, In : New England Journal of Medicine. 381, 4, p. 307-316 10 p.

Research output: Contribution to journalArticle

Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b–2 trial

International Breast Cancer Study Group and the Breast International Group, Mar 2019, In : The Lancet Oncology. 20, 3, p. 371-382 12 p.

Research output: Contribution to journalArticle

Prognostic and predictive value of androgen receptor expression in postmenopausal women with estrogen receptor-positive breast cancer: Results from the Breast International Group Trial 1-98

Kensler, K. H., Regan, M. M., Heng, Y. J., Baker, G. M., Pyle, M. E., Schnitt, S. J., Hazra, A., Kammler, R., Thürlimann, B., Colleoni, M., Viale, G., Brown, M. & Tamimi, R. M., Feb 22 2019, In : Breast Cancer Research. 21, 1, 30.

Research output: Contribution to journalArticle

Open Access

Quality of life under extended continuous versus intermittent adjuvant letrozole in lymph node-positive, early breast cancer patients: the SOLE randomised phase 3 trial

on behalf of the SOLE Investigators, May 14 2019, In : British Journal of Cancer. 120, 10, p. 959-967 9 p.

Research output: Contribution to journalArticle

Quality of life under extended continuous versus intermittent adjuvant letrozole in lymph node-positive, early breast cancer patients: the SOLE randomised phase 3 trial

on behalf of the SOLE Investigators, May 14 2019, In : British Journal of Cancer. 120, 10, p. 959-967 9 p.

Research output: Contribution to journalArticle

Quality of life under extended continuous versus intermittent adjuvant letrozole in lymph node-positive, early breast cancer patients: the SOLE randomised phase 3 trial: British Journal of Cancer

Ribi, K., Luo, W., Colleoni, M., Karlsson, P., Chirgwin, J., Aebi, S., Jerusalem, G., Neven, P., Di Lauro, V., Gomez, H. L., Ruhstaller, T., Abdi, E., Biganzoli, L., Müller, B., Barbeaux, A., Graas, M-P., Rabaglio, M., Francis, P. A., Foukakis, T., Pagani, O. & 10 others, Graiff, C., Vorobiof, D., Maibach, R., Di Leo, A., Gelber, R. D., Goldhirsch, A., Coates, A. S., Regan, M. M., Bernhard, J. & Investigators, O. B. O. T. SOLE., 2019, In : Eur. J. Cancer. 120, 10, p. 959-967 9 p.

Research output: Contribution to journalArticle

2018

A randomized phase II study evaluating different maintenance schedules of nab-paclitaxel in the first-line treatment of metastatic breast cancer: Final results of the IBCSG 42-12/BIG 2-12 SNAP trial

on behalf of the International Breast Cancer Study Group & Cancer Trials Ireland and SOLTI Group, Mar 1 2018, In : Annals of Oncology. 29, 3, p. 661-668 8 p., mdx821.

Research output: Contribution to journalArticle

Association of Somatic Driver Alterations with Prognosis in Postmenopausal, Hormone Receptor-Positive, HER2-Negative Early Breast Cancer: A Secondary Analysis of the BIG 1-98 Randomized Clinical Trial

Luen, S. J., Asher, R., Lee, C. K., Savas, P., Kammler, R., Dell'Orto, P., Biasi, O. M., Demanse, D., Jebailey, L., Dolan, S., Hackl, W., Thuerlimann, B., Viale, G., Colleoni, M., Regan, M. M. & Loi, S., Oct 1 2018, In : JAMA oncology. 4, 10, p. 1335-1343 9 p.

Research output: Contribution to journalArticle

Axillary dissection versus no axillary dissection in patients with breast cancer and sentinel-node micrometastases (IBCSG 23-01): 10-year follow-up of a randomised, controlled phase 3 trial

International Breast Cancer Study Group Trial 23-01, Oct 1 2018, In : The Lancet Oncology. 19, 10, p. 1385-1393 9 p.

Research output: Contribution to journalArticle

Axillary dissection versus no axillary dissection in patients with breast cancer and sentinel-node micrometastases (IBCSG 23-01): 10-year follow-up of a randomised, controlled phase 3 trial

International Breast Cancer Study Group Trial 23-01, Oct 1 2018, In : The Lancet Oncology. 19, 10, p. 1385-1393 9 p.

Research output: Contribution to journalArticle

Clinical considerations of the role of palbociclib in the management of advanced breast cancer patients with and without visceral metastases

Turner, N. C., Finn, R. S., Martin, M., Im, S. A., DeMichele, A., Ettl, J., Diéras, V., Moulder, S., Lipatov, O., Colleoni, M., Cristofanilli, M., Lu, D. R., Mori, A., Giorgetti, C., Iyer, S., Huang Bartlett, C. & Gelmon, K. A., Mar 1 2018, In : Annals of Oncology. 29, 3, p. 669-680 12 p., mdx821.

Research output: Contribution to journalArticle

Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial

on behalf of the SOLE Investigators, Jan 1 2018, In : The Lancet Oncology. 19, 1, p. 127-138 12 p.

Research output: Contribution to journalArticle

Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial

Colleoni, M., Luo, W., Karlsson, P., Chirgwin, J., Aebi, S., Jerusalem, G., Neven, P., Hitre, E., Graas, M. P., Simoncini, E., Kamby, C., Thompson, A., Loibl, S., Gavilá, J., Kuroi, K., Marth, C., Müller, B., O'Reilly, S., Di Lauro, V., Gombos, A. & 31 others, Ruhstaller, T., Burstein, H., Ribi, K., Bernhard, J., Viale, G., Maibach, R., Rabaglio-Poretti, M., Gelber, R. D., Coates, A. S., Di Leo, A., Regan, M. M., Goldhirsch, A., Vandebroek, A., Berliere, M., Mitine, C., Vuylsteke, P., Borms, M., D'Hondt, R., Glorieux, P., Mebis, J., Verhoeven, D., Coibion, M., Forget, F., Duck, L., Verhoeven, D., Wyendaele, W., Barbeaux, A., Salmon, J. P., Bernardo, A., Amadori, D. & on behalf of the SOLE Investigators, Jan 1 2018, In : The Lancet Oncology. 19, 1, p. 127-138 12 p.

Research output: Contribution to journalArticle

Integration of clinical variables for the prediction of late distant recurrence in patients with estrogen receptor-positive breast cancer treated with 5 years of endocrine therapy: CTS5

Dowsett, M., Sestak, I., Regan, M. M., Dodson, A., Viale, G., Thurlimann, B., Colleoni, M. & Cuzick, J., Jul 1 2018, In : Journal of Clinical Oncology. 36, 19, p. 1941-1948 8 p.

Research output: Contribution to journalArticle

Mutational analysis of triple-negative breast cancers within the International Breast Cancer Study Group (IBCSG) Trial 22-00

Munzone, E., Gray, K. P., Fumagalli, C., Guerini-Rocco, E., Láng, I., Ruhstaller, T., Gianni, L., Kammler, R., Viale, G., Di Leo, A., Coates, A. S., Gelber, R. D., Regan, M. M., Goldhirsch, A., Barberis, M. & Colleoni, M., Jul 1 2018, In : Breast Cancer Research and Treatment. 170, 2, p. 351-360 10 p.

Research output: Contribution to journalArticle

Neoadjuvant treatment with trastuzumab and pertuzumab plus palbociclib and fulvestrant in HER2-positive, ER-positive breast cancer (NA-PHER2): an exploratory, open-label, phase 2 study

Gianni, L., Bisagni, G., Colleoni, M., Del Mastro, L., Zamagni, C., Mansutti, M., Zambetti, M., Frassoldati, A., De Fato, R., Valagussa, P. & Viale, G., Feb 1 2018, In : The Lancet Oncology. 19, 2, p. 249-256 8 p.

Research output: Contribution to journalArticle

Neoadjuvant treatment with trastuzumab and pertuzumab plus palbociclib and fulvestrant in HER2-positive, ER-positive breast cancer (NA-PHER2): an exploratory, open-label, phase 2 study

Gianni, L., Bisagni, G., Colleoni, M., Del Mastro, L., Zamagni, C., Mansutti, M., Zambetti, M., Frassoldati, A., De Fato, R., Valagussa, P. & Viale, G., Feb 2018, In : The Lancet. Oncology. 19, 2, p. 249-256 8 p.

Research output: Contribution to journalArticle

Neoadjuvant treatment with trastuzumab and pertuzumab plus palbociclib and fulvestrant in HER2-positive, ER-positive breast cancer (NA-PHER2): an exploratory, open-label, phase 2 study

Gianni, L., Bisagni, G., Colleoni, M., Del Mastro, L., Zamagni, C., Mansutti, M., Zambetti, M., Frassoldati, A., De Fato, R., Valagussa, P. & Viale, G., 2018, In : The Lancet Oncology. 19, 2, p. 249-256 8 p.

Research output: Contribution to journalArticle

Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer

Turner, N. C., Slamon, D. J., Ro, J., Bondarenko, I., Im, S-A., Masuda, N., Colleoni, M., DeMichele, A., Loi, S., Verma, S., Iwata, H., Harbeck, N., Loibl, S., André, F., Puyana Theall, K., Huang, X., Giorgetti, C., Huang Bartlett, C. & Cristofanilli, M., Nov 15 2018, In : The New England journal of medicine. 379, 20, p. 1926-1936 11 p.

Research output: Contribution to journalArticle

Predictors of prolonged benefit from palbociclib plus fulvestrant in women with endocrine-resistant hormone receptor–positive/human epidermal growth factor receptor 2–negative metastatic breast cancer in PALOMA-3

Cristofanilli, M., DeMichele, A., Giorgetti, C., Turner, N. C., Slamon, D. J., Im, S-A., Masuda, N., Verma, S., Loi, S., Colleoni, M., Theall, K. P., Huang, X., Liu, Y. & Bartlett, C. H., 2018, In : European journal of cancer. 104, p. 21-31 11 p.

Research output: Contribution to journalArticle

Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial

Tripathy, D., Im, S-A., Colleoni, M., Franke, F., Bardia, A., Harbeck, N., Hurvitz, S. A., Chow, L., Sohn, J., Lee, K. S., Campos-Gomez, S., Villanueva Vazquez, R., Jung, K. H., Babu, K. G., Wheatley-Price, P., De Laurentiis, M., Im, Y-H., Kuemmel, S., El-Saghir, N., Liu, M-C. & 6 others, Carlson, G., Hughes, G., Diaz-Padilla, I., Germa, C., Hirawat, S. & Lu, Y-S., Jul 2018, In : The Lancet. Oncology. 19, 7, p. 904-915 12 p.

Research output: Contribution to journalArticle

Tailoring adjuvant endocrine therapy for premenopausal breast cancer

Francis, P. A., Pagani, O., Fleming, G. F., Walley, B. A., Colleoni, M., Láng, I., Gómez, H. L., Tondini, C., Ciruelos, E., Burstein, H. J., Bonnefoi, H. R., Bellet, M., Martino, S., Geyer, C. E., Goetz, M. P., Stearns, V., Pinotti, G., Puglisi, F., Spazzapan, S., Climent, M. A. & 16 others, Pavesi, L., Ruhstaller, T., Davidson, N. E., Coleman, R., Debled, M., Buchholz, S., Ingle, J. N., Winer, E. P., Maibach, R., Rabaglio-Poretti, M., Ruepp, B., Di Leo, A., Coates, A. S., Gelber, R. D., Goldhirsch, A. & Regan, M. M., Jul 12 2018, In : New England Journal of Medicine. 379, 2, p. 122-137 16 p.

Research output: Contribution to journalArticle

Tailoring adjuvant endocrine therapy for premenopausal breast cancer

Francis, P. A., Pagani, O., Fleming, G. F., Walley, B. A., Colleoni, M., Láng, I., Gómez, H. L., Tondini, C., Ciruelos, E., Burstein, H. J., Bonnefoi, H. R., Bellet, M., Martino, S., Geyer, C. E., Goetz, M. P., Stearns, V., Pinotti, G., Puglisi, F., Spazzapan, S., Climent, M. A. & 16 others, Pavesi, L., Ruhstaller, T., Davidson, N. E., Coleman, R., Debled, M., Buchholz, S., Ingle, J. N., Winer, E. P., Maibach, R., Rabaglio-Poretti, M., Ruepp, B., Di Leo, A., Coates, A. S., Gelber, R. D., Goldhirsch, A. & Regan, M. M., Jul 12 2018, In : New England Journal of Medicine. 379, 2, p. 122-137 16 p.

Research output: Contribution to journalArticle

The use of breast imaging for predicting response to neoadjuvant lapatinib, trastuzumab and their combination in HER2-positive breast cancer: Results from Neo-ALTTO

Di Cosimo, S., Campbell, C., Azim, H. A., Galli, G., Bregni, G., Curigliano, G., Criscitiello, C., Izquierdo, M., de la Pena, L., Fumagalli, D., Fein, L., Vinholes, J., Ng, W. M. J., Colleoni, M., Ferro, A., Naume, B. J., Patel, A., Huober, J., Piccart-Gebhart, M. J., Baselga, J. & 1 others, de Azambuja, E., Jan 1 2018, In : European Journal of Cancer. 89, p. 42-48 7 p.

Research output: Contribution to journalArticle

2017

Acquired CYP19A1 amplification is an early specific mechanism of aromatase inhibitor resistance in ERα metastatic breast cancer

Magnani, L., Frigè, G., Gadaleta, R. M., Corleone, G., Fabris, S., Kempe, H., Verschure, P. J., Barozzi, I., Vircillo, V., Hong, S-P., Perone, Y., Saini, M., Trumpp, A., Viale, G., Neri, A., Ali, S., Colleoni, M. A., Pruneri, G. & Minucci, S., 2017, In : Nature Genetics. 49, 3, p. 444-450 7 p.

Research output: Contribution to journalArticle

Acquired CYP19A1 amplification is an early specific mechanism of aromatase inhibitor resistance in ERα metastatic breast cancer

Magnani, L., Frigè, G., Gadaleta, R. M., Corleone, G., Fabris, S., Kempe, H., Verschure, P. J., Barozzi, I., Vircillo, V., Hong, S. P., Perone, Y., Saini, M., Trumpp, A., Viale, G., Neri, A., Ali, S., Colleoni, M. A., Pruneri, G. & Minucci, S., Mar 1 2017, In : Nature Genetics. 49, 3, p. 444-450 7 p.

Research output: Contribution to journalArticle

Cholesterol, cholesterol-lowering medication use, and breast cancer outcome in the BIG 1-98 study

Borgquist, S., Giobbie-Hurder, A., Ahern, T. P., Garber, J. E., Colleoni, M., Láng, I., Debled, M., Ejlertsen, B., Von Moos, R., Smith, I., Coates, A. S., Goldhirsch, A., Rabaglio, M., Price, K. N., Gelber, R. D., Regan, M. M. & Thürlimann, B., Apr 10 2017, In : Journal of Clinical Oncology. 35, 11, p. 1179-1188 10 p.

Research output: Contribution to journalArticle

Concurrent and sequential initiation of ovarian function suppression with chemotherapy in premenopausal women with endocrine-responsive early breast cancer: An exploratory analysis of TEXT and SOFT

Regan, M. M., Walley, B. A., Francis, P. A., Fleming, G. F., Láng, I., Gómez, H. L., Colleoni, M., Tondini, C., Pinotti, G., Salim, M., Spazzapan, S., Parmar, V., Ruhstaller, T., Abdi, E. A., Gelber, R. D., Coates, A. S., Goldhirsch, A. & Pagani, O., Jan 1 2017, In : Annals of Oncology. 28, 9, p. 2225-2232 8 p.

Research output: Contribution to journalArticle

Concurrent and sequential initiation of ovarian function suppression with chemotherapy in premenopausal women with endocrine-responsive early breast cancer: An exploratory analysis of TEXT and SOFT

Regan, M. M., Walley, B. A., Francis, P. A., Fleming, G. F., Láng, I., Gómez, H. L., Colleoni, M., Tondini, C., Pinotti, G., Salim, M., Spazzapan, S., Parmar, V., Ruhstaller, T., Abdi, E. A., Gelber, R. D., Coates, A. S., Goldhirsch, A. & Pagani, O., Jan 1 2017, In : Annals of Oncology. 28, 9, p. 2225-2232 8 p.

Research output: Contribution to journalArticle

Concurrent and sequential initiation of ovarian function suppression with chemotherapy in premenopausal women with endocrine-responsive early breast cancer: An exploratory analysis of TEXT and SOFT

Regan, M. M., Walley, B. A., Francis, P. A., Fleming, G. F., Láng, I., Gómez, H. L., Colleoni, M., Tondini, C., Pinotti, G., Salim, M., Spazzapan, S., Parmar, V., Ruhstaller, T., Abdi, E. A., Gelber, R. D., Coates, A. S., Goldhirsch, A. & Pagani, O., 2017, In : Annals of Oncology. 28, 9, p. 2225-2232 8 p.

Research output: Contribution to journalArticle